Approval sought to repurpose Hepatitis C drug for COVID-19 in India
FILE PHOTO: A healthcare worker collects a coronavirus disease (COVID-19) test swab sample from a man as others watch, at a temporary shelter for the homeless in New Delhi, India, March 31, 2021. REUTERS/Adnan Abidi/File Photo
BENGALURU — India’s Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.
About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data.
The drug, known as Pegylated Interferon alpha-2b and branded as ‘PegiHep’ by Cadila, was originally approved for liver disease Hepatitis C and launched in India 10 years ago. It is being repurposed to treat COVID-19.
The news comes as daily coronavirus infections are surging to new highs in India, which has the world’s third-highest caseload after the United States and Brazil. India has so far reported close to 12.5 million infections and more than 164,000 deaths.
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
